dihexa iupac name Dihexa Capsules 10mg (30ct) |

Untreated Controls Preclinical injury models % reduction in healing time Tendon Transection (Rat Achilles model)50% Skin Wound Closure (Alkali burn model)45% Muscle Crush Injury (Rat quadriceps)40% Safety Data Safety Profile from Research What preclinical and early clinical studies report Preclinical Safety Summary LD50Not achieved Acute toxicityNone observed Chronic toxicityNone in 6-month studies Organ toxicityNone detected Human IV pilot (n=2)No adverse effects Cardiac/hepatic/renalNo effects detected Regulatory & Risk Considerations FDA statusUnapproved drug WADA statusBanned since 2022 (S0) Human trialsPhase 1 only Long-term effectsUnknown in humans Pro-angiogenic riskTheoretical unstudied Australia/NZPrescription only No lethal dose was reached in preclinical toxicology studies

Governing Law and Disputes These Terms are governed by applicable United States law and the law of the state in which BGX is legally organized, without regard to conflict-of-law rules, except where mandatory consumer law requires otherwise

Though uncommon, some users report experiencing copper uglies from GHK-Cu or other copper peptides

[6] DSIP and Cancer Cells Researchers have explored the possibility of mitigating the onset of cancer cell proliferation through exposure to DSIP